On September 11, 2024 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, reported that Jim Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, presented at the H.C. Wainwright 26 th Annual Global Investment Conference (Press release, Xenetic Biosciences, SEP 11, 2024, https://ir.xeneticbio.com/news/detail/150/xenetic-biosciences-inc-presents-at-the-h-c-wainwright-26th-annual-global-investment-conference [SID1234646517]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The video webcast of the presentation is now accessible on the Events page in the Investors section of the Company’s website (www.XeneticBio.com) and will be archived for 90 days.